Workflow
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
ImmuCellImmuCell(US:ICCC) Globenewswireยท2025-07-09 12:00

Core Viewpoint - ImmuCell Corporation reported preliminary unaudited sales results for Q2 2025, showing significant growth in product sales across various time periods compared to the same periods in 2024 [1][3]. Sales Performance - Total sales for the three-month period ended June 30, 2025, reached $6.4 million, an increase of $972,000 or 18% from $5.5 million in the same period of 2024 [3]. - For the six-month period ended June 30, 2025, sales totaled $14.5 million, up by $1.8 million or 14% from $12.7 million in 2024 [3]. - Sales for the nine-month period ended June 30, 2025, were $22.3 million, reflecting a $4.4 million increase or 25% compared to $17.8 million in 2024 [3]. - Over the twelve-month period ended June 30, 2025, total sales reached $28.3 million, an increase of $5.1 million or 22% from $23.2 million in 2024 [3]. Production and Inventory Management - The company has successfully increased production output, meeting current customer demand and reducing the order backlog to under $100,000 as of June 30, 2025, down from approximately $3.4 million on May 6, 2025 [4]. - The recent sales pace is attributed to the replenishment of the distribution pipeline after a period of supply shortages, allowing the company to ship within one week of order receipt [4]. Future Capacity and Product Development - The company is evaluating additional investments to increase production capacity by 33% to approximately $40 million annually to meet potential demand growth in the North American dairy and beef markets [5]. - ImmuCell is initiating Investigational Product use of Re-Tain to test market acceptance, although this is not expected to generate significant revenue [5]. - The company has submitted a Non-Administrative New Animal Drug Application (NADA) and is addressing inspectional observations at its contract manufacturer's facilities, which is critical for NADA approval [5]. Upcoming Events - A conference call is scheduled for August 15, 2025, to discuss the unaudited financial results for the quarter ended June 30, 2025 [6][7].